Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized , placebo-controlled study to evaluate the safety and
tolerability of AVT001, and to assess AVT001 as a potential treatment for type 1 diabetes
(T1D). The trial will involve approximately 24 new-onset T1D subjects.